Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GI-102 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- GI Innovation
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
GI-102 + pembrolizumab is an investigational combination therapy for advanced or metastatic solid tumors. GI-102 is a novel bi-specific Fc fusion protein that combines the CD80 ectodomain with an interleukin-2 (IL-2) variant, attached via a human IgG4 Fc region. The CD80 component targets tumor and immune cells, blocks CTLA-4 on regulatory T (Treg) cells, and inhibits PD-L1 via CD80, while the IL-2 variant stimulates NK and CD8+ T cell proliferation with reduced Treg impact by abolishing IL-2Rα affinity. Pembrolizumab is a well-established anti-PD-1 monoclonal antibody (marketed as KEYTRUDA) that inhibits the PD-1 immune checkpoint pathway, restoring T-cell antitumor activity. This combination is being clinically investigated for immunotherapy-resistant solid tumors, especially metastatic liver cancer, melanoma, and renal cell carcinoma[1][2][3][4][5].
- Brand names
- KEYTRUDA
- Other names
- GI-102 + KEYTRUDA
02
Targets
CD80 (T-lymphocyte activation antigen CD80)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)IL2RB (IL-2 receptor beta chain)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on GI-102 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GI-102 + pembrolizumab.